However, tranilast could block dietary-ether-lipid induced mobility (Fig. 7B), which is consistent with research [46] describing TRPV2 activation by plasmalogens (PE O − ; 16:0; 18:1) in breast cancer cells. Here, TRPV2 is linked to breast carcinoma.